[Rheumatology: what's new in 2024].

In 2024, CD19-CAR T cells are ubiquitous in rheumatology, with incredible therapeutic results in cases of severe and refractory disease. This major advance confirms the interest of the B lymphocyte as a therapeutic target, and also suggests the real possibility of a drug-free remission, at the price of minor and minimal side effects for the time being. However, the necessary perspective is still lacking for a therapy that remains out of reach because of its price. On the other hand, the availability of targeted treatments offering real corticosteroid sparing benefits seems imminent for gigantocellular arteritis and polymyalgia rheumatica, with very promising results and treatments already used on a daily basis, notably JAK inhibitors, anti-IL17 and sarilumab.